By: IPP Bureau
Last updated : June 17, 2026 10:41 am
Generic launch targets a US$19 million market in United States, strengthening Glenmark’s institutional and injectable product portfolio in North America
Glenmark Pharmaceuticals Inc., USA has announced the launch of Methylene Blue Injection USP in the United States, further expanding its institutional medicines portfolio.
The newly launched product is bioequivalent and therapeutically equivalent to the reference listed drug ProvayBlue, marketed by Provepharm SAS under NDA 204630.
According to IQVIA sales data for the 12-month period ending April 2026, the U.S. market for ProvayBlue Injection generated approximately US$19 million in annual sales, highlighting the commercial opportunity for generic alternatives.
Marc Kikuchi, President & Business Head, North America said, “The launch of Methylene Blue Injection USP reflects Glenmark’s ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. mrket.”